Benzgalantamine is under clinical development by AlphaCognition and currently in Pre-Registration for Alzheimer’s Disease. According to GlobalData, Pre-Registration drugs for Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Benzgalantamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Benzgalantamine overview
Benzgalantamine (ALPHA-1062, Memogain) is under development for the treatment of dementia associated with Alzheimer's disease and mild traumatic brain injury. The drug candidate is administered through intranasal route, oral and sublingual route in the form of tablets. It targets acetylcholinesterase and neuronal acetylcholine receptor subunit alpha-7. Memogain is a pro-drug of galantamine, a natural compound. The drug candidate is a new chemical entity (NCE).
AlphaCognition overview
AlphaCognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Coloumbia, Canada.
For a complete picture of Benzgalantamine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
